SCHEMBL19949124

SCHEMBL19949124

CNC(=O)OCc1cc(C)c(Br)c(F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 4/20 0.36
TOP2B Q02880 4/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM4E B2RXH2 1/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
MAPT P10636 1/20 0.34
STAT3 P40763 1/20 0.34
NOD2 Q9HC29 1/20 0.34
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33
MGLL Q99685 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19949252 0.76 MMP1 (0.48) TOP2ATOP2BRAB9ASMN1; SMN2MEN1
SCHEMBL28049165 0.75 MAOA (0.50) TOP2ATOP2BNPC1RAB9ALMNA
SCHEMBL24716096 0.75 CYP4F2 (0.38) TOP2ATOP2BNPC1RAB9ASMN1; SMN2
SCHEMBL19948906 0.74 TOP2A (0.32) TOP2ATOP2BNPC1RAB9ASMN1; SMN2
SCHEMBL28268333 0.74 TACR1 (0.46) TOP2ATOP2BNPC1RAB9ASMN1; SMN2
SCHEMBL28266629 0.73 TOP2A (0.44) TOP2ATOP2BNPC1RAB9AMAPT
SCHEMBL26428984 0.72 ADRB2 (0.38) TOP2ATOP2BNPC1RAB9ASMN1; SMN2
SCHEMBL29843355 0.71 NTRK1 (0.34) KDM4EMAPTHDAC3HDAC1HDAC2
SCHEMBL19949144 0.71 NTRK1 (0.34) KDM4EMAPTHDAC3HDAC1HDAC2
SCHEMBL13930295 0.71 ALDH1A1 (0.38) TOP2ATOP2BNPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11891388-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2024-02-06 US disclosed
US-11866426-B2 Benzothiazole compounds and uses thereof INCYTE CORPORATION (US) 2024-01-09 US disclosed
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 US disclosed
EP-4119558-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF Incyte Corporation (US) 2023-01-18 EP disclosed
US-11542265-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2023-01-03 US disclosed
US-20220227752-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2022-07-21 US disclosed
EP-3510032-B1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORP (US) 2022-07-06 EP disclosed
US-11242343-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2022-02-08 US disclosed
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-09 US disclosed
US-20210371425-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-02 US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 US disclosed
WO-2019051199-A1 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS INCYTE CORPORATION (US) 2019-03-14 WO disclosed
US-20190076401-A1 CYANOINDAZOLE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-03-14 US disclosed
WO-2018049214-A9 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-10-18 WO disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
WO-2018049152-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed
WO-2018049200-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed
WO-2018049214-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 TOP2A 1622/4885TOP2B 2094/4885NPC1 754/4885
US-11242343-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 TOP2A 1622/4885TOP2B 2094/4885NPC1 754/4885
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PDK2 TOP2A 1102/4885TOP2B 1411/4885NPC1 779/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 TOP2A 1622/4885TOP2B 2094/4885NPC1 754/4885
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 TOP2A 1622/4885TOP2B 2094/4885NPC1 754/4885
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 TOP2A 1622/4885TOP2B 2094/4885NPC1 754/4885
US-20220227752-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 TOP2A 1622/4885TOP2B 2094/4885NPC1 754/4885
US-11542265-B2 Pyrazolopyrimidine compounds and uses thereof PDXK, PCK1, PDK2 TOP2A 1102/4885TOP2B 1411/4885NPC1 779/4885
US-11891388-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 TOP2A 1622/4885TOP2B 2094/4885NPC1 754/4885
US-11866426-B2 Benzothiazole compounds and uses thereof PDXK, PCK1, HIPK1 TOP2A 2300/4885TOP2B 2587/4885NPC1 600/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 TOP2A 1622/4885TOP2B 2094/4885NPC1 754/4885
US-20190076401-A1 CYANOINDAZOLE COMPOUNDS AND USES THEREOF PCK1, PDXK, PHKG1 TOP2A 1092/4885TOP2B 1514/4885NPC1 400/4885
US-20210371425-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PDK2 TOP2A 1102/4885TOP2B 1411/4885NPC1 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.